Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Non-Current Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other Non-Current Assets over the past 15 years, most recently at $6.6 million for Q2 2025.

  • Quarterly results put Other Non-Current Assets at $6.6 million for Q2 2025, up 15.79% from a year ago — trailing twelve months through May 2025 was $6.6 million (up 15.79% YoY), and the annual figure for FY2025 was $6.6 million, up 15.79%.
  • Other Non-Current Assets for Q2 2025 was $6.6 million at Lifecore Biomedical, Inc. \De\, up from $4.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for LFCR hit a ceiling of $169.4 million in Q2 2021 and a floor of $2.6 million in Q4 2024.
  • Median Other Non-Current Assets over the past 5 years was $4.2 million (2023), compared with a mean of $22.3 million.
  • Peak annual rise in Other Non-Current Assets hit 7755.61% in 2021, while the deepest fall reached 98.23% in 2021.
  • Lifecore Biomedical, Inc. \De\'s Other Non-Current Assets stood at $3.1 million in 2021, then skyrocketed by 1378.82% to $45.6 million in 2022, then crashed by 91.07% to $4.1 million in 2023, then crashed by 36.96% to $2.6 million in 2024, then surged by 156.25% to $6.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $6.6 million (Q2 2025), $4.9 million (Q1 2025), and $2.6 million (Q4 2024) per Business Quant data.